Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.
Bottom Line: Regular and isophane insulin (NPH), glibenclamide, metformin and gliclazide were the DU-90 drugs in 2012.Metformin, glibenclamide and regular/NPH insulin combination therapy were affordable throughout the study period (∼0.4, ∼0.1, ∼0.3 of minimum daily wage, respectively).While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.Show MeSH
Related in: MedlinePlus
Mentions: Treatment with regular and NPH insulin was consistently affordable during the study period (0.1–0.6 minimum daily wage) but premixed insulin only became affordable during the past 3 years. Treatment with novel insulin preparations including premixed aspart insulin and aspart/glargine combination has never been affordable since their presence on the market. In 2012, treatment with premixed aspart insulin cost 4.8 minimum daily wages and combination therapy with aspart and glargine insulin required 5.8 minimum daily wages. Figures 5 and 6 illustrate the pattern of diabetes medicines affordability over the study period.
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.